editor
immunotherapi
har
preexist
anticanc
immun
respons
target
immun
checkpoint
pathway
particularli
program
death
pathway
shown
remark
clinic
activ
across
sever
tumor
type
includ
nsclc
sever
drug
target
pathway
current
clinic
develop
two
agent
nivolumab
pembrolizumab
us
food
drug
agencyapprov
use
advancedstag
nsclc
clinic
trial
agent
immunemedi
pneumon
seen
nearli
patient
patient
interstiti
lung
diseas
ild
elig
particip
trial
agent
concern
advers
outcom
report
literatur
safeti
immunotherapi
patient
preexist
ild
report
case
patient
nsclc
concomit
idiopath
pulmonari
fibrosi
ipf
treat
nivolumab
man
diagnosi
ipf
nearli
decad
first
found
left
lower
lobe
nodul
follow
serial
imag
comput
tomographi
found
progress
increas
size
mm
fludeoxyglucos
f
maximum
standard
uptak
valu
fludeoxyglucos
f
hilar
mediastin
lymphadenopathi
found
positron
emiss
tomographycomput
tomographi
bronchoscopi
endobronchi
ultrasonographi
reveal
hilar
mediastin
lymph
node
involv
transbronchi
biopsi
confirm
moder
differenti
squamou
cell
carcinoma
left
lower
lobe
stage
consider
patient
poor
pulmonari
function
statu
underw
videoassist
nodulectomi
earli
neg
margin
unev
postop
cours
patholog
examin
reveal
moder
differenti
squamou
cell
carcinoma
clear
margin
background
lung
show
emphysema
sever
pulmonari
fibrosi
patchwork
pattern
fibroblast
foci
well
foci
parenchym
scar
microscop
honeycomb
chang
consist
diagnosi
combin
ipf
emphysema
adjuv
chemotherapi
recommend
surveil
conduct
imag
followup
scan
month
show
develop
new
peripher
nodul
measur
cm
lingula
addit
peribronchi
nodular
opac
measur
mm
left
upper
lobe
left
hilar
lymphadenopathi
bronchoscopi
transbronchi
biopsi
confirm
squamou
cell
carcinoma
necrosi
left
hilar
lymph
node
patient
underli
sever
ild
concurr
chemoradi
consid
safe
system
therapi
carboplatin
docetaxel
initi
poor
toler
chemotherapi
sever
fatigu
skin
reaction
docetaxel
two
cycl
chemotherapi
mild
progress
diseas
left
lower
lobe
tumor
test
program
death
ligand
patient
tumor
posit
addit
posit
tumorassoci
macrophag
began
receiv
nivolumab
septemb
initi
nivolumab
pulmonari
function
test
show
diffus
capac
lung
carbon
monoxid
given
liter
oxygen
nasal
cannula
toler
nivolumab
without
signific
toxic
signific
advers
event
mild
shrinkag
tumor
stabl
respons
tumor
per
respons
evalu
criteria
solid
tumor
fig
improv
exercis
toler
stabl
slightli
improv
oxygen
requir
interestingli
positron
emiss
tomographi
scan
month
treatment
nivolumab
show
modest
improv
compar
pretreat
baselin
scan
fig
toler
nivolumab
well
good
diseas
control
month
time
present
hospit
progress
short
breath
cough
fever
found
new
bilater
infiltr
bronchoscopi
evalu
workup
reveal
infect
coronaviru
infect
oxygen
requir
increas
liter
oxygen
nasal
cannula
prolong
hospit
week
respiratori
support
care
improv
symptom
howev
consider
sever
decondit
declin
perform
statu
nivolumab
discontinu
transit
hospic
die
month
later
ipf
progress
excess
remodel
pulmonari
alveolar
hyperplasia
associ
deposit
extracellular
matrix
ipf
result
inflammatori
process
character
chronic
inflamm
disclosur
dr
velcheti
report
person
fee
bristolmy
squibb
outsid
submit
work
alveolar
epitheli
hyperplasia
result
clinic
physiolog
derang
characterist
ipf
strike
similar
pathobiolog
dire
clinic
outcom
ipf
lung
cancer
play
role
control
inflammatori
respons
injuri
normal
lung
tissu
could
critic
pathogenesi
ipf
lung
cancer
risk
factor
smoke
occup
environment
exposur
result
stimulu
produc
episod
acut
lung
injuri
follow
patholog
wound
heal
predispos
genet
mutat
includ
atypia
dysplasia
ultim
develop
ipf
lung
cancer
agent
import
class
agent
treat
patient
nsclc
drug
well
toler
fewer
advers
event
compar
cytotox
chemotherapi
howev
caus
uniqu
class
side
effect
call
immunerel
toxic
pulmonari
toxic
agent
common
patient
nsclc
patient
tumor
type
possibl
due
impair
immun
toler
result
smokinginduc
chang
normal
lung
clinic
trial
agent
exclud
patient
underli
ild
patient
ipf
increas
risk
lung
cancer
patient
advancedstag
nsclc
limit
treatment
option
import
consid
treatment
agent
appropri
knowledg
first
case
nsclc
concomit
diagnosi
ild
treat
nivolumab
good
diseas
control
safe
outcom
without
exacerb
ild
howev
studi
need
establish
safeti
agent
target
pathway
patient
interstiti
lung
diseas
monica
khunger
md
depart
intern
medicin
cleveland
clinic
cleveland
ohio
vamsidhar
velcheti
md
depart
hematolog
oncolog
cleveland
clinic
cleveland
ohio
